Cross Vendor vs. Single Vendor Automation for Drug Discovery: Which Scales With Screening Volume?
As drug discovery programs grow, automation decisions become increasingly strategic. Many laboratories begin with a small number of instruments from a single manufacturer, only to discover that expanding screening capacity requires technologies from multiple vendors. Once automation infrastructure is established, however, changing direction becomes expensive, disruptive, and technically challenging.
Selecting the right lab automation solutions early can determine how efficiently a laboratory scales from pilot studies to high-throughput screening (HTS). The decision is no longer simply about hardware compatibility. It affects workflow flexibility, integration costs, future procurement, and long-term operational efficiency. Understanding the advantages and tradeoffs of cross-vendor and single-vendor automation helps biotech organizations build automation strategies that support future research rather than limit it.
Few drug discovery laboratories purchase every automation component from one manufacturer. Research requirements frequently dictate selecting the best instrument for each application, resulting in laboratories that combine technologies from multiple vendors.
A typical drug discovery automation environment may include:
Each platform contributes unique capabilities that support specific experimental needs. While this approach provides scientific flexibility, it also creates integration challenges. Different communication protocols, software environments, and control systems can make workflow coordination increasingly complex as laboratories expand.
This is why automation strategy must consider orchestration alongside hardware selection.
As compound libraries expand and screening campaigns become more sophisticated, flexibility becomes one of the most valuable characteristics of an automation environment.
Cross-vendor lab automation solutions allow laboratories to select equipment based on scientific performance instead of software compatibility. This flexibility provides several long-term advantages.
Researchers can choose instruments that best fit assay requirements without being restricted to one manufacturer’s product portfolio.
Labs can introduce additional automation as research demands evolve without replacing existing infrastructure.
Current equipment continues delivering value because new systems integrate with existing workflows rather than forcing complete replacement.
As new laboratory technologies emerge, organizations can incorporate them without rebuilding their automation ecosystem.
At Retisoft, we believe automation software should enable laboratories to connect diverse instruments rather than forcing them into proprietary ecosystems. This approach helps organizations preserve flexibility while supporting long-term growth.
Single-vendor automation environments often simplify initial implementation. Hardware and software are designed to work together, reducing early integration complexity.
However, challenges can emerge as laboratories move from pilot projects to large-scale HTS operations.
Vendor lock-in may limit:
For example, a laboratory may identify a high-performance imaging system that significantly improves assay quality but discover it integrates poorly with its existing proprietary automation environment.
Over time, these constraints may require laboratories to compromise either scientific objectives or operational flexibility.
Cross-vendor environments reduce this risk by supporting broader technology choices throughout the lifecycle of the laboratory.
Drug discovery workflows rarely involve simple, linear processes.
A single assay may require:
Each transition depends on successful coordination between instruments.
In a robotics and automation laboratory, integration becomes increasingly important because workflow interruptions affect downstream processes throughout the laboratory.
Regardless of whether equipment comes from one vendor or several, laboratories need automation software capable of coordinating:
Without intelligent orchestration, even highly automated laboratories may experience unnecessary delays, idle equipment, and increased manual intervention.
Effective laboratory robotics and automation depends as much on workflow coordination as it does on individual hardware performance.
The most appropriate automation strategy depends on the maturity and operational goals of the laboratory.
Organizations building their first automated workflows may benefit from simpler environments that minimize implementation complexity. Single-vendor ecosystems can provide a faster starting point for laboratories with limited automation resources and relatively stable workflows.
However, even at this stage, organizations should evaluate how easily their chosen platform can integrate future technologies.
As screening programs expand, laboratories often require additional instruments and more specialized automation capabilities. Cross-vendor environments become increasingly attractive because they allow organizations to select technologies based on evolving scientific needs rather than vendor limitations.
Contract Research Organizations and Contract Development and Manufacturing Organizations frequently support multiple clients with diverse assay requirements. Their workflows change regularly, making flexibility essential.
For these organizations, cross-vendor lab automation services often provide significant operational advantages by supporting varied instrumentation and adaptable workflows across multiple projects.
At Retisoft, we work with organizations at every stage of growth, helping them integrate existing instruments into coordinated automation environments that scale with research demands.
There is no universal answer to whether cross-vendor or single-vendor automation is the better choice. Both approaches offer distinct advantages depending on laboratory size, workflow complexity, and long-term growth objectives.
Single vendor environments may simplify initial deployment and reduce early integration requirements. Cross-vendor automation, however, generally provides greater flexibility, protects existing equipment investments, and supports evolving research needs as screening programs expand.
The most effective decision framework considers:
Rather than evaluating automation solely from a hardware perspective, laboratories should assess how well their chosen platform supports coordinated workflows over time. Selecting the right lab automation solutions today can help prevent costly infrastructure changes as research programs mature.
Latest Blogs
